Abbott Reports Results of MitraClip & TriClip Device in Multiple Studies for the Treatment of Patients with Heart Failure
Shots:
- The 1yr. results from the (EXPAND) study showed that MitraClip TEER was effective at treating leaky valves in patients with secondary MR, MR reduction to ≤1+ MR (81.3%-97.2%), improvements in NYHA class & QoL from baseline, comparable all-cause mortality & HF hospitalization rates
- The 30-day results from the (TRILUMINATE) & (bRIGHT) trials showed that TriClip & TriClip G4 TEER systems reduced TR & improve QoL, high rate of implant (98%), acute procedural (91%), 64% two-grade TR reduction, NYHA functional class I/II (69%), 57% improvement from baseline of 12%
- The company will present TVT outcomes from the (EXPAND) study of MitraClip & hemodynamic results from the (Portico NG) study of the Navitor TAVI system for AS
Ref: Abbott | Image: Abbott
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
